Gossamer bio announces fourth quarter and full-year 2019 financial results and provides business update

Gossamer bio announces fourth quarter and full-year 2019 financial results and provides business update.q4 loss per share $0.89.q4 earnings per share estimate $-0.86 -- refinitiv ibes data.gossamer bio - cash, cash equivalents & marketable securities totaled $401.8 million at year-end 2019.due to ongoing covid-19 viral pandemic, phase 2 study in patients with pah to likely commence in second half of year.gossamer bio - in response to ongoing covid-19 viral pandemic, planned series of cost-optimization initiatives.gossamer bio - see cash, cash equivalents & marketable securities to be sufficient to fund operating & capital expenditures to middle of 2022.
GOSS Ratings Summary
GOSS Quant Ranking